8-K 1 shire8k043003.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2003 Shire Pharmaceuticals Group plc -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) England and Wales -------------------------------------------------------------------------------- (State or other jurisdiction of incorporation) 0-29630 98-0359573 ----------------------------------- ---------------------------------------- (Commission File Number) (IRS Employer Identification No.) Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP England -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip code) Registrant's telephone number, including area cod 44 1256 894 000 --------------- -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) -2- Item 7. Financial Statements and Exhibits (c) Exhibits. The following exhibit is filed herewith: 99.1 Press Release dated May 1, 2003, reporting results for the first quarter ended March 31, 2003. Item 9. Regulation FD Disclosure The information set forth below is being filed pursuant to Item 12 of Form 8-K but is being provided under this Item 9 pursuant to SEC interim filing guidance dated March 27, 2003. On May 1, 2003, Shire Pharmaceuticals Group plc (the "Company") issued a press release announcing the Company's results for the quarter ended March 31, 2003. The press release is attached as Exhibit 99.1 to this Report, is incorporated herein by reference and shall be deemed "filed" for purposes of the Securities Exchange Act of 1934, as amended. -3- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 1, 2003 SHIRE PHARMACEUTICALS GROUP PLC By: /s/ Angus C. Russell ------------------------------- Name: ANGUS RUSSELL Title: Group Finance Director EXHIBIT INDEX Number Description 99.1 Press Release dated May 1, 2003, reporting results for the first quarter ended March 31, 2003.